Journal Article > ResearchFull Text
PLoS Negl Trop Dis. 29 November 2012; Volume 6 (Issue 11); DOI:10.1371/journal.pntd.0001920
Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, et al.
PLoS Negl Trop Dis. 29 November 2012; Volume 6 (Issue 11); DOI:10.1371/journal.pntd.0001920
Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use.